SLC33A1

Across TCGA pan-cancer cohorts, SLC33A1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC33A1 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher SLC33A1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC33A1 expression acts as an unfavorable survival marker.

CESC, OV, and UCEC are the cancer types where SLC33A1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.388	0.878	<.001	42	view →
OV	OS	Median	II,III,IV	0.021	0.844	<.001	36	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	II,III,IV	0.135	0.663	.015	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC33A1–CESC (OS)

Open the CESC breakdown →